307 related articles for article (PubMed ID: 34213777)
1. Exploiting epigenetic dependencies in ovarian cancer therapy.
Coughlan AY; Testa G
Int J Cancer; 2021 Nov; 149(10):1732-1743. PubMed ID: 34213777
[TBL] [Abstract][Full Text] [Related]
2. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
3. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer.
Leitner K; Tsibulak I; Wieser V; Knoll K; Reimer D; Marth C; Fiegl H; Zeimet AG
Sci Rep; 2020 Nov; 10(1):20412. PubMed ID: 33230143
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.
Li J; Wang W; Zhang Y; Cieślik M; Guo J; Tan M; Green MD; Wang W; Lin H; Li W; Wei S; Zhou J; Li G; Jing X; Vatan L; Zhao L; Bitler B; Zhang R; Cho KR; Dou Y; Kryczek I; Chan TA; Huntsman D; Chinnaiyan AM; Zou W
J Clin Invest; 2020 May; 130(5):2712-2726. PubMed ID: 32027624
[TBL] [Abstract][Full Text] [Related]
6. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
[TBL] [Abstract][Full Text] [Related]
7. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
[TBL] [Abstract][Full Text] [Related]
8. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion.
Yi X; Guo J; Guo J; Sun S; Yang P; Wang J; Li Y; Xie L; Cai J; Wang Z
Sci Rep; 2017 Jun; 7(1):3568. PubMed ID: 28620234
[TBL] [Abstract][Full Text] [Related]
9. Targeted epigenetic therapies: the next frontier?
Tuma RS
J Natl Cancer Inst; 2010 Dec; 102(24):1824-5. PubMed ID: 21139098
[No Abstract] [Full Text] [Related]
10. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
Press JZ; De Luca A; Boyd N; Young S; Troussard A; Ridge Y; Kaurah P; Kalloger SE; Blood KA; Smith M; Spellman PT; Wang Y; Miller DM; Horsman D; Faham M; Gilks CB; Gray J; Huntsman DG
BMC Cancer; 2008 Jan; 8():17. PubMed ID: 18208621
[TBL] [Abstract][Full Text] [Related]
11. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
Guan B; Wang TL; Shih IeM
Cancer Res; 2011 Nov; 71(21):6718-27. PubMed ID: 21900401
[TBL] [Abstract][Full Text] [Related]
12. EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
Zong X; Wang W; Ozes A; Fang F; Sandusky GE; Nephew KP
Cancer Res; 2020 Oct; 80(20):4371-4385. PubMed ID: 32816909
[TBL] [Abstract][Full Text] [Related]
13. Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.
Jones BA; Varambally S; Arend RC
Mol Cancer Ther; 2018 Mar; 17(3):591-602. PubMed ID: 29726819
[TBL] [Abstract][Full Text] [Related]
14. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic Therapy for Epithelioid Sarcoma.
Rothbart SB; Baylin SB
Cell; 2020 Apr; 181(2):211. PubMed ID: 32302562
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.
Wang Y; Chen SY; Colborne S; Lambert G; Shin CY; Santos ND; Orlando KA; Lang JD; Hendricks WPD; Bally MB; Karnezis AN; Hass R; Underhill TM; Morin GB; Trent JM; Weissman BE; Huntsman DG
Mol Cancer Ther; 2018 Dec; 17(12):2767-2779. PubMed ID: 30232145
[TBL] [Abstract][Full Text] [Related]
17. Epigenomic Reprogramming toward Mesenchymal-Epithelial Transition in Ovarian-Cancer-Associated Mesenchymal Stem Cells Drives Metastasis.
Fan H; Atiya HI; Wang Y; Pisanic TR; Wang TH; Shih IM; Foy KK; Frisbie L; Buckanovich RJ; Chomiak AA; Tiedemann RL; Rothbart SB; Chandler C; Shen H; Coffman LG
Cell Rep; 2020 Dec; 33(10):108473. PubMed ID: 33296650
[TBL] [Abstract][Full Text] [Related]
18. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
[TBL] [Abstract][Full Text] [Related]
19. EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains.
Donaldson-Collier MC; Sungalee S; Zufferey M; Tavernari D; Katanayeva N; Battistello E; Mina M; Douglass KM; Rey T; Raynaud F; Manley S; Ciriello G; Oricchio E
Nat Genet; 2019 Mar; 51(3):517-528. PubMed ID: 30692681
[TBL] [Abstract][Full Text] [Related]
20. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
Bitler BG; Aird KM; Garipov A; Li H; Amatangelo M; Kossenkov AV; Schultz DC; Liu Q; Shih IeM; Conejo-Garcia JR; Speicher DW; Zhang R
Nat Med; 2015 Mar; 21(3):231-8. PubMed ID: 25686104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
